NRNP 6665 WU Wk 3 Treating Anxiety Prescribing for Children & Adolescents

NRNP 6665 WU Wk 3 Treating Anxiety Prescribing for Children & Adolescents

Aripiprazole is a major and FDA-approved drug in the treatment of childhood-onset schizophrenia spectrum disorder. Aripiprazole is primarily an antipsychotic medication. This medication has typically been shown to be effective, particularly in reducing the signs and symptoms of childhood-onset schizophrenia spectrum disorder. However, in some cases, the drug may cause some side effects in the patients involved. Asenapine is an off-label treatment for the disorder. This medication is commonly sold under the brand names Saphris and others. As an antipsychotic medication, Asenapine effectively treats schizophrenia and, more importantly, acute mania associated with bipolar disorder in children and adolescents (Hilt & Nussbaum, 2016). Aripiprazole and Asenapine, in general, are thought to significantly reduce specific risks and symptoms of childhood-onset schizophrenia spectrum disorder. However, each of these drugs has its own set of advantages and disadvantages, both of which must be considered when deciding which drug to use in which circumstances.

Side effects are a major risk assessment factor to consider when making treatment decisions. Typically, side effects can be caused by a variety of factors or situations that have varying effects on the people involved. Understanding side effects will assist in making informed decisions that will ensure effectiveness in reducing the negative impacts and risks associated with a specific medical decision. One significant advantage of FDA-approved drugs is that they are generally effective. They may, however, have some side effects, such as weight gain, diabetes, and Herat failure. FDA-approved drugs are also prohibitively expensive (CriticalThinkRx. 2019, June 9). This means that they are often inaccessible in certain situations, making it one of their most important and difficult factors to consider. Off-label drugs, on the other hand, may be ineffective in reducing the disorder’s signs and symptoms. One of their advantages is that they are typically less expensive than FDA-approved alternatives.

Clinical practice guidelines for childhood-onset schizophrenia spectrum disorder have a significant impact on the overall performance, responses, and outcomes of patients with this disorder. Most practice guidelines focus on specific recommendations that will ensure affectedness in optimizing the care of involved individuals, particularly when informed by a systematic review of specific pieces of evidence and, most importantly, conducting an assessment of specific harms and benefits of other available treatment options in general (Thapar et al., 2015). In this case, the primary goal is to ensure effectiveness in improving patients’ overall experiences while also improving care, quality of life, and, most importantly, the general response to the type of care provided for the affected patient (Zakhari, 2020). In this case, healthcare providers recognize that, rather than focusing on and dictating a one-size-fits-all approach to caring for the affected children, involved clinical practice guidelines ensure effectiveness by providing an effective way to evaluate the quality of the relevant scientific literature and, most importantly, an understanding of specific risks and benefits associated with the type of treatment being used. The purpose of such information is to provide healthcare practitioners with a reliable and effective method of selecting the most appropriate care for all patients, particularly by focusing on these patients’ preferences.

References

Hilt, R. J., & Nussbaum, A. M. (2016). DSM-5 pocket guide for child and adolescent mental health. American Psychiatric Association Publishing.

Thapar, A., Pine, D. S., Leckman, J. F., Scott, S., Snowling, M. J., & Taylor, E. A. (2015). Rutter’s child and adolescent psychiatry (6th ed.). Wiley Blackwell.

Zakhari, R. (2020). The psychiatric-mental health nurse practitioner certification review manual. Springer.

CriticalThinkRx. (2019, June 9). Module 2: Use of psychotropics with youth_prevalence and concerns [Video]. YouTube. https://youtu.be/NRef-g4Ding

ORDER A PLAGIARISM-FREE PAPER HERE

We’ll write everything from scratch

---

For this Assignment, you consider these questions and others as you explore FDA-approved (“on the label”) pharmacological treatments, non-FDA-approved (“off-label”) pharmacological treatments, and nonpharmacological treatments for disorders in children and adolescents.

Recommend one FDA-approved drug, one off-label drug, and one nonpharmacological intervention for treating your assigned disorder in children and adolescents.

Explain the risk assessment you would use to inform your treatment decision-making. What are the risks and benefits of FDA-approved medicine? What are the risks and benefits of the off-label drug?

Explain whether clinical practice guidelines exist for this disorder and if so, use them to justify your recommendations. If not, explain what information you would need to take into consideration.

Support your reasoning with at least three scholarly resources, one each on the FDA-approved drug, the off-label, and a non-medication intervention for the disorder. Attach the PDFs of your sources.

Children and adolescents with panic disorder.